There is a number that pharmaceutical executives discuss constantly in private and reference obliquely in public. It is not a price. It is the distance between two prices — the Wholesale Acquisition Cost a manufacturer publishes and the net revenue it actually retains after every discount, rebate, chargeback, and fee has been extracted along the distribution chain. This distance is the gross-to-net spread, and for many branded drugs in the United States, it has grown so large that the list price and the realized price describe fundamentally different commercial realities.
The arithmetic is disorienting. A branded specialty drug with a WAC of $80,000 per year might generate net manufacturer revenue of $35,000 after Medicaid rebates, commercial rebates to PBMs, 340B chargebacks, prompt-pay discounts, patient assistance program offsets, and distribution fees are subtracted. The remaining $45,000 — more than half the published price — evaporates into a complex web of contractual obligations that span government programs, commercial contracts, and channel economics. This is not an edge case. For many branded drugs with established competition, gross-to-net spreads of forty to sixty percent have become routine.
The net price — what the manufacturer retains after subtracting most concessions across all market segments — is confidential. Manufacturers disclose gross revenue and net revenue in quarterly filings, from which analysts can calculate an aggregate gross-to-net percentage. But the composition of the spread — how much goes to Medicaid, how much to commercial rebates, how much to 340B, how much to distribution — is proprietary. Investors model it. Competitors estimate it. Nobody outside the manufacturer knows it with certainty.
This opacity creates a structural problem for everyone who needs to understand drug costs. Payers negotiating rebates cannot benchmark their own contracts against the market because the market’s net prices are hidden. Legislators citing list prices in drug pricing debates are citing numbers that increasingly bear no relationship to actual transaction economics. Patients whose cost-sharing is calculated as a percentage of WAC are subsidizing the rebate architecture that benefits everyone except them.
The mechanism that widens the spread is self-reinforcing. A manufacturer facing competitive pressure in a therapeutic category can defend market share by increasing rebates to PBMs rather than reducing WAC. The PBM passes some of the rebate to the plan sponsor, retains some as margin, and places the higher-rebate drug on a preferred formulary tier. The manufacturer maintains or increases WAC to preserve negotiating headroom for future rebate increases, even as net revenue remains flat or declines. The list price rises. The net price may not. The spread widens.
This dynamic explains a phenomenon that confuses casual observers of the pharmaceutical market: list prices that increase annually by five to ten percent while manufacturer net revenue per unit grows modestly or not at all. The list price increase is not a price increase in the economic sense. It is a renegotiation of the rebate structure in which the manufacturer and the PBM agree to exchange larger discounts for larger headline prices, preserving the financial equilibrium between them while inflating the number that drives patient cost-sharing.
The consequences cascade. The 340B program — which requires manufacturers to sell covered outpatient drugs to eligible entities at or below a ceiling price tied to AMP — sees its discount deepen as WAC rises, because the mandatory rebate calculation amplifies the gap. Manufacturers argue that 340B has expanded far beyond its original intent, absorbing an increasingly large share of their gross-to-net waterfall. Covered entities counter that the program provides essential funding for safety-net care. Both claims are accurate, and neither resolves the structural tension.
Medicaid rebates follow a parallel trajectory. The unit rebate amount for branded drugs is the greater of 23.1 percent of AMP or the difference between AMP and the best price offered to any commercial customer. As commercial rebates increase, the best price may decline, pulling the Medicaid rebate upward as well. The gross-to-net spread on Medicaid business for some branded drugs can exceed one hundred percent of AMP — meaning the manufacturer effectively pays Medicaid to dispense the drug after accounting for the rebate obligation. This is not theoretical. It has been documented for drugs with aggressive commercial rebating strategies and high Medicaid utilization.
For pharmaceutical manufacturers, gross-to-net management has evolved from an accounting exercise into a core strategic discipline. Dedicated GTN forecasting teams model the interaction between list price changes, rebate obligations, channel mix, and payer contracts across every market segment. The models are sensitive to assumptions about utilization patterns, formulary access, and competitive dynamics that can shift quarter to quarter. A manufacturer’s net price for a given drug is not a single number — it is a distribution across channels, payers, and programs, with each segment carrying different GTN characteristics. The average net price reported in financial disclosures is a weighted composite that may not describe any single transaction accurately.
The Inflation Reduction Act introduces a new variable. The Maximum Fair Price for drugs selected for Medicare negotiation is capped at a percentage of non-federal AMP, bypassing the WAC-based architecture entirely. For manufacturers of selected drugs, this creates a parallel pricing track in which the negotiated Medicare price and the commercial WAC-based price coexist. Whether MFP will compress gross-to-net spreads for selected drugs or simply add another layer of complexity to an already labyrinthine system depends on implementation details that are still evolving.
The bubble metaphor is imperfect but instructive. A bubble implies an eventual correction — a moment when the distance between the stated value and the underlying reality becomes unsustainable. In pharmaceutical gross-to-net dynamics, the correction is not a collapse but a slow restructuring. Regulatory interventions like the IRA, state drug pricing transparency laws, and payer shifts toward net-price contracting are all applying pressure to the spread from different directions. Whether they will deflate the bubble or merely redistribute its contents is the central uncertainty in pharmaceutical pricing today.
What is certain is that any analysis of drug pricing that begins and ends with WAC is analyzing a fiction. The real economics live in the gross-to-net spread — in the rebates, chargebacks, discounts, and fees that transform a published price into a realized one. The spread is where strategy happens, where value is redistributed, and where the interests of manufacturers, payers, intermediaries, and patients collide. It is also where the data is thinnest, the transparency lowest, and the stakes highest.
